Total assets have contracted significantly to $3.4 million as of 2026Q1, while the emergence of $2.4 million in goodwill amidst $111.8 million in accumulated losses raises concerns regarding asset quality.
| Total Current Assets | 536.67K | 967.97K | 3.43M | 3.03M | 8.53M | 12.09M | 8.21M | 6.54M | 6.95M | 5.88M | 195.59K | 126.62K | 404.42K |
| Cash & Short-Term Investments | 356.46K | 762.37K | 3.23M | 2.83M | 4.89M | 9.46M | 7.23M | 6.17M | 6.47M | 5.6M | 144.95K | 19.13K | 156.44K |
| Cash Only | 356.46K | 762.37K | 3.23M | 2.83M | 4.89M | 9.46M | 7.23M | 6.17M | 6.47M | 5.6M | 144.95K | 19.13K | 156.44K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.85K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 7.11 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 2.64M | 1.28M | 589.62K | 113.44K | 59.44K | 191.68K | 40.1K | 99K | 238.99K |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 404.92 | 62.06 | 54.24 | 336.61 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 130.7K | 273.31K | 14.25K | 10.54K | 8.49K | 8.99K |
| Total Non-Current Assets | 2.9M | 2.89M | 1.02M | 3.72M | 747.46K | 780.53K | 557.24K | 641.17K | 273.23K | 241.55K | 295.17K | 360.1K | 298.52K |
| Property, Plant & Equipment | 464.75K | 504.46K | 647.29K | 465.87K | 741.47K | 774.54K | 551.25K | 641.17K | 273.23K | 241.55K | 295.17K | 360.1K | 298.52K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | 0.02x | 1.46x | 1.75x | 3.92x | 1.87x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5.99K | 2.38M | 371.4K | 3.26M | 5.99K | 5.99K | 5.99K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 3.44M | 3.85M | 4.45M | 6.75M | 9.27M | 12.87M | 8.76M | 7.18M | 7.22M | 6.12M | 490.76K | 486.72K | 702.93K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | 0.00x | 0.06x | 1.05x | 2.90x | 0.80x |
| Asset Growth % | -154.68% | -13.44% | -34.08% | -27.17% | -27.97% | 46.89% | 22.14% | -0.64% | 17.95% | 1147.8% | 0.83% | -30.76% | - |
| Total Current Liabilities | 835.44K | 750.96K | 605.23K | 903.1K | 1.7M | 1.54M | 986.66K | 2.07M | 974.58K | 848.21K | 1.38M | 236.42K | 97.6K |
| Accounts Payable | 456.84K | 382.97K | 269.68K | 360.4K | 613.96K | 791.05K | 402.91K | 1.28M | 631.47K | 780.26K | 227.74K | 80.94K | 11.5K |
| Days Payables Outstanding | 3.16K | - | - | - | - | - | - | - | - | 1.65K | 352.41 | 44.35 | 16.2 |
| Short-Term Debt | 133.95K | 0 | 0 | 28.48K | 28.48K | 117.13K | 83.87K | 364.26K | 0 | 0 | 949.98K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -23 | 0 | 206.81K | 0 | 0 |
| Other Current Liabilities | 244.65K | 238.61K | 169.72K | 148.79K | 158.93K | 0 | 0 | 235.35K | 22.51K | 0 | 72K | 0 | 22.33K |
| Current Ratio | 0.64x | 1.29x | 5.67x | 3.36x | 5.00x | 7.83x | 8.32x | 3.15x | 7.13x | 6.93x | 0.14x | 0.54x | 4.14x |
| Quick Ratio | 0.64x | 1.29x | 5.67x | 3.36x | 3.45x | 7.00x | 7.72x | 3.10x | 7.07x | 6.71x | 0.11x | 0.12x | 1.69x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.24K | - | - | - |
| Total Non-Current Liabilities | 815.86K | 842.72K | 1.29M | 192.06K | 365.92K | 546.63K | 608.99K | 342.81K | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 28.48K | 337.08K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 1.52M | 362.97K | 487.48K | 192.06K | 365.92K | 518.15K | 271.91K | 342.81K | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 488.6K | 479.75K | 799.28K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.65M | 1.59M | 1.89M | 1.1M | 2.07M | 2.09M | 1.6M | 2.42M | 974.58K | 848.21K | 1.38M | 236.42K | 97.6K |
| Total Debt | 461.21K | 492.35K | 584.42K | 394.4K | 546.63K | 796.09K | 769.34K | 773.27K | 23 | 0 | 949.98K | 0 | 0 |
| Net Debt | 104.74K | -270.01K | -2.65M | -2.44M | -4.34M | -8.67M | -6.46M | -5.4M | -6.47M | -5.6M | 805.02K | -19.13K | -156.44K |
| Debt / Equity | 0.26x | 0.22x | 0.23x | 0.07x | 0.08x | 0.07x | 0.11x | 0.16x | 0.00x | - | - | - | - |
| Debt / EBITDA | -0.07x | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.02x | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -611.04x | - | -49.45x | -4.65x | -12.43x | - | - | - | - |
| Total Equity | 1.79M | 2.26M | 2.56M | 5.66M | 7.2M | 10.78M | 7.17M | 4.76M | 6.25M | 5.28M | -893.77K | 250.3K | 605.33K |
| Equity Growth % | -190.81% | -11.73% | -54.76% | -21.45% | -33.19% | 50.42% | 50.59% | -23.81% | 18.44% | 690.25% | -457.08% | -58.65% | - |
| Book Value per Share | 1.49 | 2.87 | 2.28 | 3.31 | 3.73 | 5.27 | 7.47 | 12.70 | 27.74 | 26.95 | -4.58 | 1.28 | 19.76 |
| Total Shareholders' Equity | 1.79M | 2.26M | 2.56M | 5.66M | 7.2M | 10.78M | 7.17M | 4.76M | 6.25M | 5.28M | -893.77K | 250.3K | 605.33K |
| Common Stock | 122 | 116 | 53 | 1.04K | 317 | 212 | 3.4K | 842 | 742 | 392 | 253 | 253 | 200 |
| Retained Earnings | -111.78M | -110.47M | -103.44M | -91.93M | -81.87M | -68.69M | -57.34M | -45.22M | -27.69M | -17.9M | -12.52M | -9.74M | -7.46M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 5.23K | 6.07K | 13.86K | 10.79K | 43.53K | -405.95K | -337.63K | -276.15K | -208.09K | -188.67K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity depletion risk
As reported in financial statements, the company's total assets have contracted from $10.4 million in 2024Q2 to $3.4 million by 2026Q1, reflecting a consistent erosion of the balance sheet as the firm consumes capital to fund its pre-revenue developmental activities and regulatory clinical trial requirements.
The persistent decline in total assets suggests that the company is struggling to maintain a stable capital base while awaiting commercialization. This downward trajectory in asset value, coupled with the absence of revenue, indicates that the business quality remains highly speculative and dependent on external funding.
According to recent SEC filings, the company's cash position has plummeted to $356,500 as of 2026Q1, resulting in a current ratio of 0.64, which indicates that current liabilities now exceed available liquid assets and poses a significant threat to the firm's ongoing operational continuity.
The sharp decline in the current ratio from 6.10 in 2024Q3 to 0.64 in 2026Q1 highlights a rapid deterioration in the company's ability to cover short-term obligations. Investors should monitor this liquidity crunch closely, as it may necessitate immediate dilutive financing or strategic restructuring to avoid a going concern qualification.
Based on reported figures, total equity has shrunk to $1.8 million in 2026Q1 from a peak of $9.0 million in 2024Q2, a trend driven by accumulated losses of $111.8 million that continue to erode the company's book value and shareholder capital base over time.
The consistent growth in accumulated deficits underscores the high cost of the company's R&D-heavy business model. The reliance on equity financing to bridge this gap suggests that existing shareholders face ongoing dilution risks as the firm attempts to sustain its operations without a commercial revenue stream.
As indicated by the balance sheet, the emergence of $2.4 million in goodwill as of 2026Q1 warrants investigation, as it represents a significant portion of total assets for a company that has yet to demonstrate a viable commercial product or sustainable cash-generating capability.
The sudden appearance of goodwill on the balance sheet may suggest past acquisition activity that has not yet translated into operational success. This intangible asset carries a high risk of future impairment charges, which could further weaken the company's already strained equity position if the underlying technology fails to gain market traction.
Quick answers to the most common questions about buying NDRA stock.
As of 2025, ENDRA Life Sciences Inc. (NDRA) had total assets of $3.9M including $1.0M in current assets.
ENDRA Life Sciences Inc. (NDRA) carries total debt of $0.5M, offset by $0.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
ENDRA Life Sciences Inc. (NDRA) has total shareholders' equity (book value) of $2.3M ($2.87 book value per share). Book value represents the net worth of the company belonging to common stock holders.
ENDRA Life Sciences Inc. (NDRA) reported a current ratio of 1.29x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.